Cargando…

Monitor unit optimization in RapidArc plans for prostate cancer

Intensity‐modulated radiation therapy (IMRT) has become a standard treatment for prostate cancer based on the superior sparing of the bladder, rectum, and other surrounding normal tissues compared to three‐dimensional conformal radiotherapy, despite the longer delivery time and the increased number...

Descripción completa

Detalles Bibliográficos
Autores principales: Clemente, Stefania, Cozzolino, Mariella, Chiumento, Costanza, Fiorentino, Alba, Caivano, Rocchina, Fusco, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5714413/
https://www.ncbi.nlm.nih.gov/pubmed/23652245
http://dx.doi.org/10.1120/jacmp.v14i3.4114
_version_ 1783283582803902464
author Clemente, Stefania
Cozzolino, Mariella
Chiumento, Costanza
Fiorentino, Alba
Caivano, Rocchina
Fusco, Vincenzo
author_facet Clemente, Stefania
Cozzolino, Mariella
Chiumento, Costanza
Fiorentino, Alba
Caivano, Rocchina
Fusco, Vincenzo
author_sort Clemente, Stefania
collection PubMed
description Intensity‐modulated radiation therapy (IMRT) has become a standard treatment for prostate cancer based on the superior sparing of the bladder, rectum, and other surrounding normal tissues compared to three‐dimensional conformal radiotherapy, despite the longer delivery time and the increased number of monitor units (MU). The novel RapidArc technique represents a further step forward because of the lower number of MUs per fraction and the shorter delivery time, compared to IMRT. This paper refers to MU optimization in RA plans for prostate cancer, using a tool incorporated in Varian TPS Eclipse. The goal was to get the lowest MU RA plan for each patient, keeping a well‐defined level of PTV coverage and OAR sparing. Seven prostate RA plans (RA MU‐Optimized) were retrospectively generated using the MU optimization tool in Varian Eclipse TPS. Dosimetric outcome and nontarget tissue sparing were compared to those of RA clinical plans (RA Clinical) used to treat patients. Compared to RA Clinical, RA MU‐Optimized plans resulted in an about [Formula: see text] reduction in MU. The total integral dose (ID) to each nontarget tissue (but not the penile bulb) showed a consistent average relative reduction, statistically significant only for the femoral heads. Within the intermediate dose region (40–60 Gy), ID reductions ([Formula: see text]) were found for the rectum, while a slight but significant ([Formula: see text]) higher ID was found for the whole body. Among the remaining data, the mean dose to the bladder was also reduced ([Formula: see text]). Plans using MU optimization are clinically applicable and more MU efficient, ameliorating the exposure of the rectum and the bladder to intermediate doses. PACS number: 87
format Online
Article
Text
id pubmed-5714413
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-57144132018-04-02 Monitor unit optimization in RapidArc plans for prostate cancer Clemente, Stefania Cozzolino, Mariella Chiumento, Costanza Fiorentino, Alba Caivano, Rocchina Fusco, Vincenzo J Appl Clin Med Phys Radiation Oncology Physics Intensity‐modulated radiation therapy (IMRT) has become a standard treatment for prostate cancer based on the superior sparing of the bladder, rectum, and other surrounding normal tissues compared to three‐dimensional conformal radiotherapy, despite the longer delivery time and the increased number of monitor units (MU). The novel RapidArc technique represents a further step forward because of the lower number of MUs per fraction and the shorter delivery time, compared to IMRT. This paper refers to MU optimization in RA plans for prostate cancer, using a tool incorporated in Varian TPS Eclipse. The goal was to get the lowest MU RA plan for each patient, keeping a well‐defined level of PTV coverage and OAR sparing. Seven prostate RA plans (RA MU‐Optimized) were retrospectively generated using the MU optimization tool in Varian Eclipse TPS. Dosimetric outcome and nontarget tissue sparing were compared to those of RA clinical plans (RA Clinical) used to treat patients. Compared to RA Clinical, RA MU‐Optimized plans resulted in an about [Formula: see text] reduction in MU. The total integral dose (ID) to each nontarget tissue (but not the penile bulb) showed a consistent average relative reduction, statistically significant only for the femoral heads. Within the intermediate dose region (40–60 Gy), ID reductions ([Formula: see text]) were found for the rectum, while a slight but significant ([Formula: see text]) higher ID was found for the whole body. Among the remaining data, the mean dose to the bladder was also reduced ([Formula: see text]). Plans using MU optimization are clinically applicable and more MU efficient, ameliorating the exposure of the rectum and the bladder to intermediate doses. PACS number: 87 John Wiley and Sons Inc. 2013-05-06 /pmc/articles/PMC5714413/ /pubmed/23652245 http://dx.doi.org/10.1120/jacmp.v14i3.4114 Text en © 2013 The Authors. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/3.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Radiation Oncology Physics
Clemente, Stefania
Cozzolino, Mariella
Chiumento, Costanza
Fiorentino, Alba
Caivano, Rocchina
Fusco, Vincenzo
Monitor unit optimization in RapidArc plans for prostate cancer
title Monitor unit optimization in RapidArc plans for prostate cancer
title_full Monitor unit optimization in RapidArc plans for prostate cancer
title_fullStr Monitor unit optimization in RapidArc plans for prostate cancer
title_full_unstemmed Monitor unit optimization in RapidArc plans for prostate cancer
title_short Monitor unit optimization in RapidArc plans for prostate cancer
title_sort monitor unit optimization in rapidarc plans for prostate cancer
topic Radiation Oncology Physics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5714413/
https://www.ncbi.nlm.nih.gov/pubmed/23652245
http://dx.doi.org/10.1120/jacmp.v14i3.4114
work_keys_str_mv AT clementestefania monitorunitoptimizationinrapidarcplansforprostatecancer
AT cozzolinomariella monitorunitoptimizationinrapidarcplansforprostatecancer
AT chiumentocostanza monitorunitoptimizationinrapidarcplansforprostatecancer
AT fiorentinoalba monitorunitoptimizationinrapidarcplansforprostatecancer
AT caivanorocchina monitorunitoptimizationinrapidarcplansforprostatecancer
AT fuscovincenzo monitorunitoptimizationinrapidarcplansforprostatecancer